'Pay for Delay'

The EU's competition commissioner issued the final report from investigating the delays in generic drugs coming to the market, reports the Wall Street Journal's Health Blog. The report acknowledged that innovation difficulties and regulation affect the time it takes to get a generic to market and suggested that the EU have a single patent and litigation system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.